Monte Rosa Therapeutics Reports Pricing Of $100M Public Offering
Portfolio Pulse from Benzinga Newsdesk
Monte Rosa Therapeutics has announced the pricing of a $100 million public offering, which includes 10.638 million shares of common stock at $4.70 per share and pre-funded warrants at $4.6999 per warrant.
May 16, 2024 | 11:16 am
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Monte Rosa Therapeutics has priced a $100 million public offering, including 10.638 million shares at $4.70 each and pre-funded warrants at $4.6999 each.
The public offering will raise significant capital for Monte Rosa Therapeutics, which could be used for further development and operations. However, the dilution of shares might offset any positive impact in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100